AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21575187 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight at initiation of anti-TB treatment (<35 kg)
Number of subjects: 6450
Study 21575187 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient category
Number of subjects: 6450
Study 21575187 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of enrollment
Number of subjects: 6450
Study 21575187 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment center
Number of subjects: 6450
Study 17990218 — intervention group
Group type: EXPERIMENTAL
Intervention: Single carbohydrate feeding (SF) - 2.5 g carbohydrate per kg body mass, 3 hours before exercise
Number of subjects: 8
Study 17990218 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple carbohydrate feedings (MF) - 2.5 g carbohydrate per kg body mass in 5 equal doses at 3, 2.5, 2, 1.5, and 1 hour before exercise
Number of subjects: 8
Study 17990218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) - liquid placebo 3 hours before exercise
Number of subjects: 8
Study 17048976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300mg
Number of subjects: 60
Study 12973962 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds Ratio
Number of subjects: 0
Study 12973962 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Risk
Number of subjects: 0
Study 11009490 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program (excluding forearm exercise)
Number of subjects: 12
Study 9301390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal testing
Number of subjects: 212
Study 9301390 — intervention group
Group type: COMPARATOR
Intervention: Prick testing
Number of subjects: 212
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with cold aluminium surface at -7 degrees C
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with cold aluminium surface at 0 degrees C
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with cold aluminium surface at +7 degrees C
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact pressure at 0.1 N
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact pressure at 5.9 N
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact pressure at 9.8 N
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Large contact material mass (3559 g)
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Small contact material mass (108 g)
Number of subjects: 20
Study 7957157 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body thermal balance
Number of subjects: 20
Study 3112038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maltose solution at 0.2 g/kg/h
Number of subjects: 2
Study 3112038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maltose solution at 0.4 g/kg/h
Number of subjects: 2
Study 28991513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (D) + Trametinib (T) 150/2
Number of subjects: 99
Study 28991513 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib (D) monotherapy
Number of subjects: 99
Study 28525977 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) target of <140 mmHg
Number of subjects: 270
Study 28525977 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) target of <180 mmHg
Number of subjects: 270
Study 25899785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (30-45 mg daily in 28-day cycles)
Number of subjects: 30
Study 23810939 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Light Diet enhanced with reduced energy/fat pre-packaged meals (eSLD)
Number of subjects: 150
Study 23810939 — intervention group
Group type: COMPARATOR
Intervention: Recommended care reduced energy/fat meal plan diet (RC)
Number of subjects: 150
Study 22010238 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 6% glycerin
Number of subjects: 864
Study 22010238 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude glycerin samples with high levels of fatty acids (24% and 35%)
Number of subjects: 864
Study 22010238 — intervention group
Group type: EXPERIMENTAL
Intervention: All glycerin samples
Number of subjects: 864
Study 22010238 — intervention group
Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 864
Study 18185038 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (ankle assigned for testing)
Number of subjects: 115
Study 18185038 — intervention group
Group type: COMPARATOR
Intervention: Validation group (ankle assigned for validation)
Number of subjects: 115
Study 17010744 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol foam plus calcipotriene ointment (twice-daily for 2 weeks)
Number of subjects: 86
Study 17010744 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene (monotherapy for 2 weeks)
Number of subjects: 86
Study 17010744 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol foam (monotherapy for 2 weeks)
Number of subjects: 86
Study 17010744 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekday calcipotriene plus weekend pulse clobetasol foam (6 months)
Number of subjects: 86
Study 17010744 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (6 months)
Number of subjects: 86
Study 14700173 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed surgery with pre-operative stabilization
Number of subjects: 0
Study 14700173 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 0
Study 10918802 — intervention group
Group type: EXPERIMENTAL
Intervention: QUOROM statement checklist
Number of subjects: 0
Study 10918802 — intervention group
Group type: EXPERIMENTAL
Intervention: QUOROM statement flow diagram
Number of subjects: 0
Study 8861665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 800 mg and 200 mg
Number of subjects: 10
Study 8861665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 8861665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU)
Number of subjects: 10
Study 1297939 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg once daily for seven days
Number of subjects: 88
Study 1297939 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg once daily for seven days
Number of subjects: 88
Study 1297939 — intervention group
Group type: COMPARATOR
Intervention: Both Zopiclone and Midazolam
Number of subjects: 88
Study 6925461 — intervention group
Group type: EXPERIMENTAL
Intervention: C 1821, administered orally for 14 days
Number of subjects: 0
Study 6925461 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally for 14 days
Number of subjects: 0
Study 31303022 — intervention group
Group type: COMPARATOR
Intervention: Flat postoperative shoes
Number of subjects: 100
Study 31303022 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse camber postoperative shoes
Number of subjects: 100
Study 29436087 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional reach training combined with conventional physical therapy (30 min each, 3 days a week for 4 weeks)
Number of subjects: 16
Study 29436087 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (30 min per day, 3 days a week for 4 weeks)
Number of subjects: 16
Study 29436087 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional reach training combined with conventional physical therapy
Number of subjects: 16
Study 29436087 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 16
Study 27149954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-management standing programme with advice and support along with usual care
Number of subjects: 0
Study 27149954 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 27149954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-management standing programme
Number of subjects: 0
Study 24012203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous norepinephrine administration starting with 2 μg/kg per hour combined with 1 ml/kg per hour of Ringer's maleate solution until bladder removal, then 3 ml/kg per hour of Ringer's maleate solution (norepinephrine/low‐volume group)
Number of subjects: 166
Study 24012203 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 6 ml/kg per hour of Ringer's maleate solution throughout surgery
Number of subjects: 166
Study 21660978 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg danoprevir solution delivered to the distal small bowel and colon via an Enterion™ capsule
Number of subjects: 0
Study 21660978 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg danoprevir powder to the colon via an Enterion™ capsule
Number of subjects: 0
Study 21660978 — intervention group
Group type: COMPARATOR
Intervention: 100 mg danoprevir IR soft gel capsule
Number of subjects: 0
Study 19300424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric device (automated monitors)
Number of subjects: 3355
Study 19300424 — intervention group
Group type: COMPARATOR
Intervention: Usual care (mercury or aneroid sphygmomanometers)
Number of subjects: 3355
Study 16532880 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty approach (medication restricted to smoking cessation clinics)
Number of subjects: 40
Study 16532880 — intervention group
Group type: COMPARATOR
Intervention: Primary care approach (most smokers treated by the primary care provider)
Number of subjects: 40
Study 15567788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol combined with fentanyl (group B)
Number of subjects: 100
Study 15567788 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol (group A)
Number of subjects: 100
Study 10786107 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suture (group 1)
Number of subjects: 146
Study 10786107 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous suture (group 2)
Number of subjects: 146
Study 9378168 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (C) 400 mg/m2 every three weeks
Number of subjects: 40
Study 9378168 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 350 mg/m2, ifosfamide (I) 5 g/m2 with mesna, vincristine (V) 1.4 mg/m2, and bleomycin (B) 30 mg every ten days (CIVB arm)
Number of subjects: 40
Study 9378168 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (C)
Number of subjects: 40
Study 7903505 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 21
Study 7903505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 21
Study 7903505 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 3475430 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene)
Number of subjects: 840
Study 3475430 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 840
Study 3475430 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene) with methyldopa if blood pressure remained elevated
Number of subjects: 840
Study 3475430 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 840
Study 31538149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% prior to 0.5 mg/kg midazolam (group B)
Number of subjects: 63
Study 31538149 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam (group A)
Number of subjects: 63
Study 31538149 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (placebo) with 0.5 mg/kg midazolam (group C)
Number of subjects: 63
Study 30458625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (MVF) combined with traditional rehabilitation (30 minutes MVF + 45 minutes traditional rehabilitation)
Number of subjects: 40
Study 30458625 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (75 minutes)
Number of subjects: 40
Study 27696490 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (high, 3 μg/mL; medium, 1.5 μg/mL; low, 0.5 μg/mL; or no drug) and Remifentanil (high, 6 or 8 ng/mL; medium, 4 ng/mL; low, 2 ng/mL; or no drug)
Number of subjects: 60
Study 26203169 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming drugs
Number of subjects: 0
Study 26203169 — intervention group
Group type: COMPARATOR
Intervention: Untreated children in intervention schools
Number of subjects: 0
Study 26203169 — intervention group
Group type: COMPARATOR
Intervention: Children in nearby non-intervention schools
Number of subjects: 0
Study 24195209 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment of fire needles at bones combined with cupping and Tuina
Number of subjects: 100
Study 24195209 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 100
Study 21470872 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of anterior periaortic fat pad (AFP) during CABG (n=107)
Number of subjects: 215
Study 21470872 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of anterior periaortic fat pad (AFP) during CABG (n=108)
Number of subjects: 215
Study 21470872 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of AFP
Number of subjects: 215
Study 21470872 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of AFP
Number of subjects: 215
Study 19673337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (FOLFOX regimen) combined with Shenqi Fuzheng Injection (SFI)
Number of subjects: 152
Study 19673337 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (FOLFOX regimen) alone
Number of subjects: 152
Study 16750678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 150
Study 16750678 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (BA)
Number of subjects: 150
Study 14559725 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-lipodystrophic patients
Number of subjects: 34
Study 11288201 — intervention group
Group type: EXPERIMENTAL
Intervention: Progresse (test formulation)
Number of subjects: 24
Study 11288201 — intervention group
Group type: COMPARATOR
Intervention: Neurotin (reference formulation)
Number of subjects: 24
Study 10920901 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM (treatment group)
Number of subjects: 74
Study 10920901 — intervention group
Group type: COMPARATOR
Intervention: CHOP (control group)
Number of subjects: 74
Study 10920901 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM (treatment group) in high grade malignant NHL
Number of subjects: 74
Study 10920901 — intervention group
Group type: COMPARATOR
Intervention: CHOP (control group) in high grade malignant NHL
Number of subjects: 74
Study 8392274 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with estrogen/progesterone
Number of subjects: 54
Study 8392274 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 54
Study 3554491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg three times daily
Number of subjects: 118
Study 3554491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 29729655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention (details on dosage and duration not available)
Number of subjects: 735
Study 26769552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 500
Study 26769552 — intervention group
Group type: COMPARATOR
Intervention: Exercise Stress Testing (EST)
Number of subjects: 500
Study 25041811 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-384 single-dose (1, 8, 20, 50, 120 and 240 mg)
Number of subjects: 0
Study 25041811 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-384 multiple-dose (1, 2, 4, 8, 20, 30 and 100 mg once daily)
Number of subjects: 0
Study 25041811 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for ABT-384
Number of subjects: 0
Study 22951426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefditoren pivoxil 400mg once daily
Number of subjects: 82
Study 22951426 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone
Number of subjects: 82
Study 20079602 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0- or 7.5-mm ETT
Number of subjects: 22
Study 20079602 — intervention group
Group type: COMPARATOR
Intervention: 8.0-mm ETT
Number of subjects: 22
Study 18028385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia with subarachnoid morphine, bupivacaine, and fentanyl (MBF group)
Number of subjects: 160
Study 18028385 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus epidural analgesia (EA group)
Number of subjects: 160
Study 18028385 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and bupivacaine (MB group)
Number of subjects: 160
Study 18028385 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (M group)
Number of subjects: 160
Study 17054311 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 139
Study 17054311 — intervention group
Group type: COMPARATOR
Intervention: No preoperative radiotherapy
Number of subjects: 139
Study 12773836 — intervention group
Group type: EXPERIMENTAL
Intervention: Women Take PRIDE program (self-management intervention)
Number of subjects: 452
Study 12773836 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 452
Study 10685817 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) 100 units diluted in 1 ml saline, injected at five trigger points (0.2 ml each) via a 30 gauge needle.
Number of subjects: 26
Study 10685817 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 ml) as placebo control, injected at five trigger points.
Number of subjects: 26
Study 9086150 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 100
Study 9086150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8200182 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide
Number of subjects: 9
Study 8200182 — intervention group
Group type: COMPARATOR
Intervention: acute volume expansion alone
Number of subjects: 9
Study 3923791 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 76
Study 3923791 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 76
Study 3923791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contrast agent)
Number of subjects: 76
Study 29306877 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention (education, informatics, financial incentives)
Number of subjects: 65
Study 29306877 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of non-recruited practices)
Number of subjects: 65
Study 29306877 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention (self-reported adoption)
Number of subjects: 65
Study 29306877 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention (effectiveness)
Number of subjects: 65
Study 29306877 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention (final multivariate model)
Number of subjects: 65
Study 27631616 — intervention group
Group type: EXPERIMENTAL
Intervention: (hot‐to‐) cold shower for 30 seconds
Number of subjects: 3018
Study 27631616 — intervention group
Group type: EXPERIMENTAL
Intervention: (hot‐to‐) cold shower for 60 seconds
Number of subjects: 3018
Study 27631616 — intervention group
Group type: EXPERIMENTAL
Intervention: (hot‐to‐) cold shower for 90 seconds
Number of subjects: 3018
Study 27631616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold shower)
Number of subjects: 3018
Study 23856361 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 23856361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23856361 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients with CD for 2 years or less)
Number of subjects: 0
Study 23856361 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (patients achieving deep remission)
Number of subjects: 0
Study 22281799 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPCpre plus RIPCpost
Number of subjects: 54
Study 22281799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 19966591 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-rest intervals (SR) with a work rest ratio of approximately 1:3
Number of subjects: 34
Study 19966591 — intervention group
Group type: COMPARATOR
Intervention: Long-rest intervals (LR) with a work rest ratio of approximately 1:6
Number of subjects: 34
Study 19966591 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-rest intervals (SR)
Number of subjects: 34
Study 19966591 — intervention group
Group type: COMPARATOR
Intervention: Long-rest intervals (LR)
Number of subjects: 34
Study 18355366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Number of subjects: 202
Study 18355366 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose HT (2 mg 17 beta‐estradiol and 1 mg NETA)
Number of subjects: 202
Study 18355366 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg)
Number of subjects: 202
Study 18355366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202
Study 15680144 — intervention group
Group type: EXPERIMENTAL
Intervention: Speakers producing disambiguating cues to syntactic ambiguity in instructions (Experiment 1 and 3)
Number of subjects: 0
Study 15680144 — intervention group
Group type: EXPERIMENTAL
Intervention: Speakers' awareness of situational ambiguity (Experiment 3)
Number of subjects: 0
Study 15680144 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions with syntactic ambiguity (Experiment 1)
Number of subjects: 0
Study 15680144 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking data (Experiment 3)
Number of subjects: 0
Study 12767572 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (TTS 50 twice‐weekly)
Number of subjects: 35
Study 12767572 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 35